Evidence map›Paper›PMID 33495222›Full record

ArticleAntimicrobial agents and chemotherapy2021

Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an

Maria Siopi, David S Perlin, Maiken C Arendrup, Spyros Pournaras, Joseph Meletiadis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Breakthrough Acute Necrotizing Invasive Fungal Rhinosinusitis byJournal of fungi (Basel, Switzerland) · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Maria SiopiClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Maiken C ArendrupUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-4747-0144
Spyros PournarasClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece jmeletiadis@med.uoa.gr.ORCID 0000-0002-8869-1509
National and Kapodistrian University of Athens · GRHackensack Meridian Health · USStatens Serum Institut · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Echinocandins have been used as primary therapy of invasive aspergillosis (IA), with suboptimal results at standard dosing. Here, we explored the efficacy of dose escalation in a validated

Indexed as

Aspergillus fumigatusEchinocandinsAnidulafunginAntifungal AgentsCaspofunginHumansLipopeptidesMicrobial Sensitivity TestsAnidulafunginAntifungal AgentsCaspofunginEchinocandinsLipopeptidesantifungal agentsaspergillosisdose optimizationechinocandinin vitro PK/PD modelpharmacodynamics

Identifiers

PMID33495222
PMCPMC8097425
OpenAlexW3121821816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.